TY - JOUR
KW - Administration, Cutaneous
KW - Administration, Oral
KW - Adult
KW - Aged
KW - Biopsy
KW - Clofazimine
KW - Dapsone
KW - Drug Administration Schedule
KW - Drug Therapy, Combination
KW - Female
KW - Follow-Up Studies
KW - Health Surveys
KW - Humans
KW - Leprostatic Agents
KW - leprosy
KW - Male
KW - Medical Records
KW - Middle Aged
KW - Retrospective Studies
KW - Rifampin
KW - Secondary Prevention
KW - Treatment Outcome
KW - United States
AU - Dacso MM
AU - Jacobson RR
AU - Scollard D
AU - Stryjewska B
AU - Prestigiacomo J
AB - <p><b>OBJECTIVES: </b>To evaluate the occurrence of relapse of multibacillary leprosy after multi-drug treatment including daily rifampin.</p><p><b>METHODS: </b>A retrospective review was performed utilizing data from the National Hansen's Disease Program (NHDP) on patients with leprosy treated and followed from 1988-1997 who received multi-drug therapy including daily rifampin. The occurrence of relapse in this cohort was measured, and demographic data and various clinical variables were also gathered.</p><p><b>RESULTS: </b>Ultimately, 158 cases fulfilled the eligibility criteria. 77% of cases were multibacillary patients and were treated with 2 or 3 drug protocols at rates of 36% and 35% before and after 1992, respectively. Only one case of relapse was found, and this patient underwent 2-drug therapy versus 3-drug therapy.</p><p><b>CONCLUSION: </b>These data are remarkable for the absence of relapse with daily rifampin, as contrasted with the published experience using the WHO protocol with monthly rifampin.</p>
BT - Southern medical journal
C1 - http://www.ncbi.nlm.nih.gov/pubmed/21941157?dopt=Abstract
DA - 2011 Oct
DO - 10.1097/SMJ.0b013e31822d6014
IS - 10
J2 - South. Med. J.
LA - eng
N2 - <p><b>OBJECTIVES: </b>To evaluate the occurrence of relapse of multibacillary leprosy after multi-drug treatment including daily rifampin.</p><p><b>METHODS: </b>A retrospective review was performed utilizing data from the National Hansen's Disease Program (NHDP) on patients with leprosy treated and followed from 1988-1997 who received multi-drug therapy including daily rifampin. The occurrence of relapse in this cohort was measured, and demographic data and various clinical variables were also gathered.</p><p><b>RESULTS: </b>Ultimately, 158 cases fulfilled the eligibility criteria. 77% of cases were multibacillary patients and were treated with 2 or 3 drug protocols at rates of 36% and 35% before and after 1992, respectively. Only one case of relapse was found, and this patient underwent 2-drug therapy versus 3-drug therapy.</p><p><b>CONCLUSION: </b>These data are remarkable for the absence of relapse with daily rifampin, as contrasted with the published experience using the WHO protocol with monthly rifampin.</p>
PY - 2011
SP - 689
EP - 94
T2 - Southern medical journal
TI - Evaluation of multi-drug therapy for leprosy in the United States using daily rifampin.
VL - 104
SN - 1541-8243
ER -